<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Comparison of zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Comparison of zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Comparison of zoster vaccine live (ZVL) and recombinant zoster vaccine (RZV)</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="17%"></colgroup><colgroup width="32%"></colgroup> <tbody> <tr class="divider_bottom"> <td class="subtitle1">Vaccine</td> <td class="subtitle1">Efficacy (incidence HZ)</td> <td class="subtitle1">Systemic side effects that prevented normal everyday activities (vaccine versus placebo)</td> <td class="subtitle1">Follow-up</td> <td class="subtitle1">Comment</td> </tr> <tr class="divider_top"> <td class="divider_bottom" rowspan="2">ZVL (single dose)</td> <td>Population ≥60 years of age<sup>[1]</sup>:<br/> 51% reduction in risk of HZ compared with placebo (95% CI 44.2-57.6%; 11.12 versus 5.42 per 1000 person-years)</td> <td class="divider_bottom" rowspan="2">&lt;1% reported in post-hoc analysis<sup>[5]</sup></td> <td>3.1 years</td> <td class="divider_bottom" rowspan="2"> <p>Vaccine efficacy was significantly greater in individuals aged 60 to 69 years compared with those ≥70 years (63.9 versus 37.6%). Protection against postherpetic neuralgia was 67%<sup>[1]</sup>.</p> Observational studies found the protection from ZVL wanes significantly after 5 to 8 years (from approximately 50% to 20 to 30% for those ≥60 years of age)<sup>[6-8]</sup>. Protection against postherpetic neuralgia was maintained significantly longer.</td> </tr> <tr class="divider_bottom"> <td>Population 50 to 59 years of age<sup>[2]</sup>:<br/> 70% reduction in risk of HZ compared with placebo (95% CI 54.1-80.6%; 6.57 versus 1.99 per 1000 person-years)</td> <td>1.3 years</td> </tr> <tr> <td rowspan="2">RZV (2 doses separated by 2 months)</td> <td>Population ≥70 years of age<sup>[3]</sup>:<br/> 89% reduction in risk of HZ compared with placebo (95% CI 84.2-93.7%; 9.2 versus 0.9 per 1000 person-years)</td> <td>6 versus 2%</td> <td>3.7 years</td> <td rowspan="2"> <p>Myalgia was the most common systemic reaction.</p> Protection against postherpetic neuralgia in patients ≥70 years of age was 89%.</td> </tr> <tr> <td>Population ≥50 years of age<sup>[4]</sup>:<br/> 96.2% reduction in risk of HZ compared with placebo (95% CI 92.7-98.3%; 9.1 versus 0.3 per 1000 person-years)</td> <td>11.4 versus 2.4%</td> <td>3.2 years</td> </tr> </tbody></table></div><div class="graphic_footnotes">RZV: recombinant zoster vaccine; ZVL: zoster live vaccine; HZ: herpes zoster.</div><div class="graphic_reference">References:

<ol>
<li>Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005; 352:2271.</li>
<li>Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis 2012; 54:922.</li>
<li>Cunningham AL, Lal H, Kovac M, et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N Engl J Med 2016; 375:1019.</li>
<li>Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015; 372:2087.</li>
<li>Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety profile of a herpes zoster Vaccine. A Detailed Review of Data from CSP #403: the Shingles Prevention Study. Ann Intern Med 2010; 152:545.</li>
<li>Baxter R, Bartlett J, Fireman B, et al. Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study. Am J Epidemiol 2018; 187:161.</li>
<li>Morrison VA, Johnson GR, Schmader KE, et al. Long-term persistence of zoster vaccine efficacy. Clin Infect Dis 2015; 60:900.</li>
<li>Tseng HF, Harpaz R, Luo Y, et al. Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years. J Infect Dis 2016; 213:1872.</li>
</ol></div><div id="graphicVersion">Graphic 116904 Version 2.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
